Latest News

CHAIN Celebrates Successful ‘Chiral Chemical Synthesis in Clostridia’ Study

LONDON, UK, 10 AUGUST 2016 — CHAIN Biotechnology Ltd has successfully completed a 12-month research project entitled “Chiral Chemical Synthesis in Clostridia”. The research was supported by a grant from Innovate UK, the UK’s innovation agency.

Specifically, CHAIN has demonstrated a new way to change the stereochemistry of intracellular metabolism in Clostridia bacteria, resulting in the re-direction of carbon flow towards R-chiral chemicals rather than the natural S-form. This change in stereochemistry, referred to as the “Chiral Switch™”, resulted in the production of two new renewable chemical products; 1,3 butanediol and 3-hydroxybutyrate.

During this project, CHAIN demonstrated the technical feasibility of applying the Chiral Switch™ technology in several different species. The genetic modification was stabilised using advanced genetic tools to achieve chromosomal integration, and the fermentation conditions were optimised to increase product yield.

The chiral purity and delivery of chiral chemicals in the correct R-enantiomeric form is critical to ensure safety and efficacy, especially when formulated into nutritional and pharmaceutical products. Currently, chiral chemicals are manufactured as by-products from oil-refining through unsustainable, complex and often costly chemical synthesis processes. In contrast, CHAIN’s Chiral Switch™ technology provides a new fermentation method for the production of specific R-chiral chemicals. The technology supports a cheaper, cleaner and more sustainable route to these high value chemicals.

Clostridium is a genus of bacterium proven for industrial chemical production. Solvent producing strains have been used for commodity chemical (acetone and butanol) fermentation since the early 1900s. Recent technological breakthroughs have allowed the genetic manipulation of these economically and industrially important bacteria, unlocking their potential to make higher value fine chemicals.

Edward Green, Chief Executive says, “CHAIN uses advanced gene editing tools for Clostridia and has demonstrated for the first time the use of synthetic biology for the production of novel and specific chiral chemicals in Clostridium. Our proprietary Chiral Switch, we have exemplified and patented, is a powerful mechanism that unlocks the commercial viability of the Clostridium chassis. This important breakthrough supports the production of specific high value chiral chemicals and demonstrates CHAIN’s technology leadership with Clostridium bacteria. This innovation provides us with a significant competitive advantage for high value products and we are working with industry partners to translate the research into commercial opportunities.”



 CHAIN Biotechnology Ltd. (CHAIN) is an early-stage biotechnology Company based at Imperial College, London and the University of Nottingham. The Company aims to develop and exploit Clostridium bacteria for a wide range of high value biotechnology markets and applications. CHAIN has recruited a team of experts and assembled world class partners to build an advanced technology platform for Clostridium. The Company deploys proprietary “cutting edge” synthetic biology methods to improve production characteristics in strains selected from our unique collection of industrial strains. Quite simply CHAIN is the “Clostridia Technology Company”.

Related News

CHAIN Awarded £0.5M Grant Funding to Develop Healthcare Platform

CHAIN Biotech has been awarded £0.5M grant funding from Innovate UK, the UK’s innovation...

CHAIN Appoints New Board Members

CHAIN welcomes to its Board of Directors the recent appointment of Dr Mike McDonald...

CHAIN Finalists in Biotechnology Awards

CHAIN Biotechnology is proud to announce that it is a finalist in two competitions...

omega 3 nutritional supplements
CHAIN Obtains Grant Funding For Collaborative Projects

June 11, 2016 – London, UK. CHAIN Biotechnology Ltd has won grant funding for...

CHAIN new employees clostridium modular vectors omega 3
CHAIN Welcomes New Starters

CHAIN has hired two new world class scientific team members to expand its role...

CHAIN Secures Seed Funding and Appoints New Board Members

London, UK, 23 December, 2015 CHAIN has successfully completed its first round of seed funding...

CHAIN HPLC Analysis of Chiral Chemicals Innovate UK feasibility study for Collaboration Nation: synthetic biology and strain development of anaerobic bacteria
CHAIN Celebrates Feasibility Study Success at Collaboration Nation

CHAIN Biotech has successfully completed a feasibility study into altering bacterial metabolism to produce...

CHAIN Wins Business Interaction Voucher for clostridia strain development
CHAIN Wins Business Interaction Voucher with University of Nottingham

CHAIN Biotechnology has been awarded a £5,000 Business Interaction Voucher in partnership with the...

CHAIN launches a new grant funded research project

CHAIN has been awarded £180K from InnovateUK for a project focused on the production...

CHAIN wins award and launches new website

Award winning CHAIN Biotech launches its new website, funded by a prize voucher from...

CHAIN joins University of Nottingham Synthetic Biology Research Centre

CHAIN Biotechnology Ltd is proud to announce a new collaboration with Professor Nigel Minton’s...

CHAIN hires Research Manager

CHAIN Biotechnology Ltd welcomes Dr Dana Heldt. Dana is an experienced strain development scientist...